Medical Writing Good Pharma Bad karma
mew-150pxjpg

Volume 22, Issue 4 - Good Pharma

Bad karma

Abstract

Bad Pharma provides a hyper-critical account of the pharmaceutical industry's approach to conducting, publishing and using clinical research and development. However, its attack on the drug regulators is unfair and its examination of the medical press uncritical. In consequence, it fails to provide the appropriate solution to making results of trials more widely available. This is to make the rigour of drug regulation available to all, rather than extending the use of that mediocre medium, the medical press.

Download the full article

References

  1. Goldacre B. Bad Pharma: How drug companies mislead doctors and harm patients. London: Fourth Estate; 2012.
  2. Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med 2012;367:1355–60.
  3. International Conference on Harmonisation. Statistical principles for clinical trials (ICH E9). Stat Med 1999;18:1905–42.
  4. Senn SJ. Statistical quality in analysing clinical trials. Good Clin Pract J 2000;7:22–6.
  5. Olson CM, Rennie D, Cook D, Dickersin K, Flanagin A, Hogan JW, et al. Publication bias in editorial decision making. JAMA 2002;287:2825–8.
  6. Senn SJ. Misunderstanding publication bias: editors are not blameless after all F1000 Research 2012; 1.
  7. Senn SJ. Authors are also reviewers: problems in assigning cause for missing negative studies. F1000Research 2013; 2.
  8. Lynch JR, Cunningham MR, Warme WJ, Schaad DC, Wolf FM, Leopold SS. Commercially funded and United States-based research is more likely to be published; good-quality studies with negative outcomes are not. J Bone Ioint Surg American volume 2007;89:1010–8.
  9. Committee for Proprietary Medicinal Products. Points to consider on multiplicity issues in clinical trials. In: Points to consider on multiplicity issues in clinical trials. European Medicines Evaluation Agency: 2002.
  10. Senn S, Bretz F. Power and sample size when multiple endpoints are considered. Pharm Stat 2007;6:161–170.
  11. Lurie P, Almeida CM, Stine N, Stine AR, Wolfe SM. Financial conflict of interest disclosure and voting patterns at Food and Drug Administration Drug Advisory Committee meetings. JAMA 2006;295:1921–1928.
  12. International Committee of Medical Journal Editors. The New ICMJE Recommendations [cited 2013 Sept 11]. Available from: http://www.icmje.org/new_recommendations.html
  13. International Committee of Medical Journal Editors. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals: Roles and Responsibilities of Authors, Contributors, Reviewers, Editors, Publishers, and Owners: Defining the Role of Authors and Contributors [cited 2013 Sept 11] Available from: http://www.icmje.org/roles_a.html

Search

Articles

Good pharma
Message from the President
Transparency and the healthcare industry: The Sun is shining
Sunshine spreading across the Atlantic and over Europe
Bad karma
If a misinformed voice speaks out in the wilderness and no one refutes it, does it make a sound? A call to advocacy
The Big Pharma conspiracy theory
Editorial: Pharmaism
Legal remedies for medical ghostwriting: Imposing fraud liability on guest authors of ghostwritten articles
A decade of change: A new ISMPP has arrived
Selling evidence over the counter: Do community pharmacists engage with evidence-based medicine?
Good regulatory practice and the role(s) of a regulatory affairs professional
Profile: An interview with Dr Gustavo A. Silva on the concept of public health in medical writing and translation
AuthorAID: An international service and chance to serve
India as a hub for ethical and evidence-based medical communications
Providing value for medicines in older people
In the Bookstores
Journal Watch
The Webscout
Regulatory Writing
Medical Communications
Manuscript Writing
Out On Our Own
Erratum
The Light Stuff

Member Login

Links

The Write Stuff Archive Contact Instructions for Authors Feature Article Template (Word) Journal Policies

Editoral Board

Editor-in-Chief:

Co-Editor:

Editorial Manager

  • Victoria White (Tampa, Florida, USA)
show all +

Associate Editors:

Section Editors:

Ad-hoc Editors:

  • Amy Whereat (SpeaktheSpeech Consulting, Asnieres sur Seine, France)

Editor Emeritus: